在二次预防阿尔茨海默病临床试验中的认知查偏差
Isha Sai1, Joshua D Grill2,3,4, Kyan Younes1
1Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
概括
在阿尔茨海默病 (AD) 预防试验中使用的认知查测试可能会不成比例地排除少数民族. 像迷你精神状态检查这样的测试中的这些潜在偏差可能会影响对关键AD研究的资格.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 健康差异 在健康上的差异
背景情况:
- 阿尔茨海默病 (AD) 预防试验需要识别具有AD生物标志物证据的认知不受损的个体.
- 认知和功能查测试可能会显示对少数民族的偏见,这可能会影响试验的资格和代表性.
研究的目的:
- 检查用于阿尔茨海默病 (AD) 预防试验的认知和功能查测试中的潜在偏差.
- 调查种族和语言差异如何影响阿尔茨海默氏症临床试验的资格,特别是无症状阿尔茨海默氏症 (A4) 抗粉样蛋白治疗研究.
主要方法:
- 分析了A4研究选的6669名参与者的数据.
- 根据种族背景和测试语言分组参与者,以检查不合格原因,认知/功能测试表现和粉样蛋白阳性率的差异.
主要成果:
- 少数民族较少满足AD预防试验的资格标准.
- 在迷你精神状态检查项目性能和临床痴呆症评分功能领域观察到的差异表明了跨组的潜在测试偏差.
- 与逻辑记忆相比,自由和指导选择性提醒测试显示了更公平的排除率,在少数民族中发现了较低的粉样蛋白阳性率.
结论:
- 认知和功能查工具可能含有偏见,导致种族少数群体不成比例地被排除在阿尔茨海默病临床试验之外.
- 解决这些查偏见对于确保公平获得AD预防研究和促进多样化人群治疗发展至关重要.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.临床试验中的临床试验.认知查偏差 认知查偏差英语英语英语英语英语英语英语英语自由和带绳选择性提醒试验西班牙裔白人白人日本人 日本人 日本人 日本人神经心理学测试语言语言测试非西班牙裔亚洲人非西班牙裔黑人非拉丁裔黑人非西班牙裔白人的白色更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
34.0K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
8.2K
相关概念视频
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:30Dementia
632
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
632
02:07Blind Procedures
13.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.8K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
765
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
765